“As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it’s leveraging AI,” said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci’s generative AI platform and developing best-in-class biologics.

<p>&ldquo;As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it&rsquo;s leveraging AI,&rdquo; said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci&rsquo;s generative AI platform and developing best-in-class biologics.</p>

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Health Care by Bloomberg Intelligence

 Absci Leveraging Gen AI for Best-in-Class Antibodies

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/86b0c1b5-70e9-414e-9a09-b29101239200/transcript